A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
BTK participates in a variety of signal transduction of innate and adaptive immunity, and has
an important role in cell proliferation, differentiation and apoptosis. The impact of BTK
inhibitors on hematological malignancies and autoimmune diseases has been well studied. This
project was undertaking by Qilu Hospital of Shandong University in China. In order to report
the efficacy and safety of the selective BTK inhibitor Orelabrutinib in the management of
refractory ITP.